Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Albiglutide - GSK

Drug Profile

Albiglutide - GSK

Alternative Names: Albugon; Albumin-GLP-1 fusion protein; Albumin-glucagon-like peptide-1 fusion protein; Eperzan; GLP-1-albumin fusion protein; Glucagon-like peptide-1-albumin fusion protein; GSK 716155; Syncria®; Tanzeum

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Human Genome Sciences
  • Developer GSK
  • Class Albumins; Antihyperglycaemics; Glucagon-like peptides; Obesity therapies; Recombinant fusion proteins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Discontinued Heart failure; Type 1 diabetes mellitus

Most Recent Events

  • 16 Jan 2018 Discontinued - Phase-II for Type-1 diabetes mellitus (Adjunctive treatment, Newly diagnosed) in France, United Kingdom, Italy, Germany and Spain (SC)
  • 16 Jan 2018 Discontinued - Phase-II for Type-2 diabetes mellitus in Chile and Dominican Republic (SC)
  • 16 Jan 2018 Discontinued - Phase-III for Type-2 diabetes mellitus in Albania, Japan, Mexico, Russia, Philippines, Hong Kong, Peru, Taiwan, South Korea, Australia, Brazil, Israel, South Africa, Colombia and India (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top